GlassScriptPhysician profile
Masih Ahmed
NPI 1114345725
$1,847.88
in general payments reported to CMS, 2019-2025
17 companies · $681 in 2025
The $681 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $17.24 · 2021: $150 · 2022: $110 · 2023: $526 · 2024: $228 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $718.00 | 2021-2025 | Clareon, Hydrus Microstent, Unity |
| Bausch & Lomb Americas INC. | $195.40 | 2023-2025 | Envista Envy Iol, Miebo |
| Carl Zeiss Meditec USA, INC. | $120.81 | 2023 | Clarus |
| Glaukos Corporation | $112.76 | 2025 | Photrexa Viscous and Photrexa |
| Novartis Pharmaceuticals Corporation | $110.34 | 2021-2022 | |
| Dompe US, INC. | $103.62 | 2019 | |
| Rxsight INC | $99.94 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Tarsus Pharmaceuticals, INC. | $97.16 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $51.20 | 2023 | Acthar |
| Carl Zeiss Meditec, INC. | $48.84 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $45.48 | 2023 | Cequa |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $40.28 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $27.67 | 2025 | Tecnis Simplicity |
| Oyster Point Pharma, INC. | $26.01 | 2022 | |
| Eyevance Pharmaceuticals LLC | $21.11 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.91 | 2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masih Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.